Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating

Potential HspE7 Therapeutic Benefit

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. Preliminary evaluation of biological samples collected from the study's first and second cohorts indicates that administration of HspE7 results in an E7-specific T-cell immune response. Independent research findings recently published in the journal Gynecologic Oncology by Jeffrey Weber, M.D., Ph.D., associate director for clinical research at the University of Southern California's Norris Comprehensive Cancer Center, demonstrated that such an immune response may be associated with objective clinical responses in patients with CIN. Accordingly, Nventa believes that HspE7 may successfully treat CIN by activating and enhancing the body's natural immune system.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

As previously reported, doses administered in both study cohorts were found to be safe and well tolerated, with no serious adverse events being reported in either group. Cohort 1 was designed to establish a baseline for the study with patients in this group being administered 500 mcg of HspE7 and 50 mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. Consistent with previous preclinical studies conducted by Nventa, this dose level demonstrated anti-HspE7 antibody responses but limited T-cell responses. In cohort 2, patients were administered 500 mcg of HspE7 and 500 mcg of Poly-ICLC. In this group, 3 out of 4 patients showed anti-HspE7 antibody responses and HPV16 E7-speci
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... , SALEM, N.H., Aug. 27 ... announced today their continued commitment to educate health care professionals ... accuracy for all patients. WaveSense BGM,s uniquely employ WaveSense technology ... detect and correct for errors caused by different environmental conditions ...
... Aug. 27 Lakewood-Amedex Inc., (L-A), the ... and anti-viral products including NuBiotics, a novel family of ... and influenza, announced today that it is accelerating development ... , , Lakewood-Amedex,s nRNA product works ...
Cached Medicine Technology:WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks 2WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks 3Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 2Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 3
(Date:8/23/2014)... Los Angeles, CA (PRWEB) August 23, 2014 ... binary options trading system created by Greg Marks has ... public launch earlier this month. The commotion surrounding the ... Hendricks, prompting an investigative review. , “In ... binary options trading software systems, commonly referred to as ...
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, ... sole source of water for commercial and industrial properties. ... Brown of Archworks, LLC in Carmel, California. , This ... a water district in the State of California has approved ... AWGs at this time can now be used as a ...
(Date:8/23/2014)... Young adults in Athens, GA who find that ... up the phone and call the new helpline which can offer ... , Troubled Teen Athens is a wonderful resource for an ... the necessary steps to end substance abuse once and for all. ... to friends or peers when really they should put their faith ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen ... North Carolina. It’s no different in Wilmington, NC. Substance ... adults are falling victim to drug and alcohol dependency ... people are looking to overcome substance abuse, but don’t ... an adolescent treatment facility can be a challenge because ...
(Date:8/22/2014)... Search Engine Optimization is needed ... of search engines and get more audience and ... compared many Linux hosting suppliers and announced that ... most recommended Linux hosting suppliers for webmasters from ... buy high quality Linux hosting (including VPS and ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2
... study finds that women treated for breast cancer are at ... Published in the December 15, 2009 issue of Cancer ... study,s results indicate that breast cancer patients with dense breasts ... Previous studies indicate that women with dense breast tissue ...
... O,Brien, president of Catholics for Choice, issued the following statement ... recent weeks tells us and the American voters a lot ... to our core values, seeking to overcome the struggles ordinary ... cannot afford basic healthcare or have to choose between maintaining ...
... AARP Praises House Passage of Health Care Reform Bill ... all Americans , HARRISBURG, Penn., Nov. 8 ... of Representatives passed critical health care reform legislation that would ... that prices millions of Americans out of affordable health coverage. ...
... take you out of the game later, doctors say , ... talk of the NFL this season, sidelining such stars as ... at the American Podiatric Medical Association and American Academy of ... their feet when they play fall sports like football and ...
... of Representatives passed the Affordable Health Care for America ... American has access to quality, affordable, stable and secure ... some of the insurance industry,s worst practices, would extend ... by $104 billion over ten years. Groups representing doctors ...
... ... Company’s Mississauga, Ontario facility. , ... Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and ... a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze ...
Cached Medicine News:Health News:Breast density associated with increased risk of cancer recurrence 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:Rx for Fall Foot Injuries 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: